This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
a leading provider of clinical development technology, today announced 80% revenue growth in 2024 across enterprise customers adopting a SaaS model for portfolio-level electronic clinical outcomes assessment (eCOA) technology investments compared to study-by-study contracts. in DCT-enabled studies.
Among these transformative innovations, artificial intelligence (AI ) stands out as a major force, reshaping the fields of drug discovery , drugdevelopment, clinical trials and patient care. The clinical trials phase represents a crucial turning point in drugdevelopment, but is often characterised by inefficiencies and delays.
This expansion mirrors a trend identified in an industry report jointly published by Biofourmis and HealthXL last year, predicting widespread adoption of digital endpoints by pharmaceutical companies in drugdevelopment programs by 2030.
a leading provider of clinical development technology, today announced new data from the Tufts Center for the Study of DrugDevelopment (CSDD)s PACT Consortium links decentralized clinical trial (DCT) approaches to notably higher participation rates across multiple demographic groups. PALO ALTO, Calif.–(BUSINESS
The $55M in new funding will allow the company to further develop their AI technology and eClinical platform, Citrus, to optimize study design, automate central monitoring of study data, enable instant biostatistics, and more, as well as hiring in key areas including clinical operations and product development.
Oncology is one of the most active and fastest growing areas of drugdevelopment research, outpacing other therapeutic areas in terms of study volume, complexity, cost, and duration.
Oncology is one of the most active and fastest growing areas of drugdevelopment research, outpacing other therapeutic areas in terms of study volume, complexity, cost, and duration.
a leading provider of clinical development technology, today announced new data from the Tufts Center for the Study of DrugDevelopment (CSDD)s PACT Consortium linking decentralized clinical trial (DCT) approaches to notably higher proportional representation among select demographic subgroups. Medable Inc.,
23andMe tried to monetize its extensive genetic database by collaborating with pharmaceutical companies for drug research. While promising, drugdevelopment requires significant time and investment, delaying any financial returns and impacting the company’s short-term revenue.
The study, led by principal investigator Nitin Ohri, M.D., The study, led by principal investigator Nitin Ohri, M.D., This pilot study represents a critical step in leveraging digital health technology to enhance cancer treatment outcomes,” said John Wagner, M.D., Chief Medical Officer, Koneksa. “By
This is the pathway toward achieving human digital twins, dynamic models that not only reflect and allow health monitoring but also enhance patient stratification, improve the success rates of drugdevelopment programs, and enable treatment testing before application.
New study* reveals greater comprehension and personal engagement with enhanced e-consent PALO ALTO, Calif.–(BUSINESS The study population was diverse in gender, age, race, and geographic location. The enhanced eIC] is more appealing to me as a human being, not just a study subject,” said a 63-year-old male participant. “It
With ResponderID, we sought to disrupt the historical linear progression of drug discovery and development, rather aiming to close the loop between drugdevelopment, patient care and new drug discovery,” said Rafael Rosengarten, Ph.D., co-founder and CEO of Genialis. “We
A new study finds that antibiotic resistance adds more than $1,000 to the cost of treatment for a single patient. The study’s authors urge policymakers to support the development of new strategies to prevent infections and to support innovative antibiotic drugdevelopment.
MarketScan: Real-World Data Analytics: Offers access to longitudinal, fully-adjudicated claims data and analytics to strengthen, accelerate, and simplify real-world evidence studies. Real-World Evidence: Leverages real-world data to inform clinical decision-making and drugdevelopment.
The LEARNS study will investigate the Koneksa neuroscience solution, as well as the Beacon Biosignals platform, applied to at-home EEG, compared with in-clinic polysomnography, in neurological and sleep disorders. The study will also evaluate whether assessment combinations can identify diagnostic features at the cohort diagnostic boundary.
PicnicHealth and AllStripes pioneered a new model by working directly with patients, which enables a deeper view of each patient’s health and experience while reducing the challenges of traditional site-based studies. Originally announced October 23rd, 2023
The FDA issued a series of four patient-focused drugdevelopment (PFDD) guidance documents which outline how patient co-design needs to successfully happen. By the power vested in clinical research, the FDA now pronounces us patient and industry. You may now kiss the cancer survivor.
Furthermore, by fostering connectivity and automating tasks, DHTs reduce administrative burdens, accelerate recruitment, and improve overall trial transparency, ultimately contributing to faster and more reliable drugdevelopment. It has been used in various studies in Europe with great results.
Clinical trials, a vital component of the drugdevelopment process, were heavily disrupted because patients, often with weakened immune systems, could not visit hospitals and research sites. The COVID-19 pandemic has completely changed the way we think about clinical research and care.
Clinical trials, a vital component of the drugdevelopment process, were heavily disrupted because patients, often with weakened immune systems, could not visit hospitals and research sites. The COVID-19 pandemic has completely changed the way we think about clinical research and care.
As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drugdevelopment. Koneksa clients gain access to a team of PhDs and MDs at SSI with expertise in drugdevelopment.
We believe Evinova’s combination of scientific expertise and track record in developing AI-enabled digital technologies at scale, provides a real opportunity to fundamentally improve patient care, drive healthcare transformation and reduce carbon emissions.” Deloitte pharma study: Drop-off in returns on R&D investments.
A recent Deloitte study estimates the average cost of developing a single new drug at $2.3 Moreover, the vast majority of drug candidates do not reach the finish line, and many fail the clinical phase even though the biology works. billion in 2022, with an average 7.1-year year deployment time.
AI-powered* platform takes eCOA off the critical path to study startup for life sciences industry PALO ALTO, Calif.–(BUSINESS Early application of the technology in electronic clinical outcomes assessment (eCOA) deployments – a major delay to study startup industry-wide – is groundbreaking.
Biomarkers will help select patients whose cancer biologies are best suited to treatment with the right drug targeting the active disease mechanism. DDR inhibitors are currently being tested in preclinical and clinical studies. Debiopharm’s main activities include drugdevelopment, drug manufacturing and digital health investment.
The announcement of the deal comes after Locemia has enjoyed a series of positive trial results for nasal glucagon in 2015; the most recent study data released showed the treatment proved safe for children , ages 4 to 17, with Type 1. The acquisition is an attempt by Lilly to bolster its troubled drug pipeline.
This digital measurement model has already shown promise in early feasibility studies, and we look forward to applying this model into interventional trials with future partners and studies. Remote data collection also expands study accessibility, enabling a broader and more diverse representation of patients in clinical trials.
Furthermore, the industry witnessed a decline in the average return on investment (ROI) for R&D to as low as 1.2%, and the peak sales per asset valued just above $350 million, indicating a need to build more efficient drugdevelopment processes with the implementation of newer technologies.
Research & studies. In his studies, Type 1 diabetic patients have significantly benefited when their daily insulin regimen is supplemented with drugsdeveloped to treat Type 2 diabetes. JDRF-funded triple therapy study. The goals for this JDRF-funded study include a 1.2% A1C reduction for each patient.
For a person like me, who is impacted by a rare, neurological, and incurable disease, it’s my mission to ensure that patients’ perspectives are represented early and throughout drugdevelopment. We plan to gather these stakeholders at the upcoming Huntington Study Group conference this November 3-5 in Tampa, FL, to develop next steps.
Partnership enables deeper evidence generation in clinical trials; early success in eight big-pharma-sponsored oncology studies PALO ALTO, Calif.–(BUSINESS –(BUSINESS WIRE)– Medable Inc. , Medable, which ranked in the top 8% of software companies on the 2023 Inc. in Phase III trials, respectively.
Through this collaboration, Indivi will take over the digital management of Konectom TM in the Phase 2b LUMA study evaluating the efficacy and safety of BIIB122 in participants with early-stage Parkinson’s disease, which is being developed in collaboration with Denali Therapeutics Inc.
Regulatory Hurdles: The stringent regulatory environment in healthcare can increase development costs and delay time to market, making it less attractive to investors. Develop APIs and other integration tools to facilitate seamless data exchange. Conduct randomized controlled trials and real-world studies.
Despite the numerous scientific studies demonstrating the efficacy and safety of metformin over the years, there are still some myths and misconceptions about its safety that hinder patient acceptance and adherence. 4,5,6 These studies, on the other hand, show that metformin does not raise the risk of heart safety problems.
Overall, Palantir's software is helping to improve patient care, accelerate research, and improve drugdevelopment. Palantir's products are helping these organizations to improve patient care, accelerate research, and improve drugdevelopment. What are a few likely scenarios for Palantir in Healthcare? Have a comment?
Another study of the consenting process of 35 clinical trials (representing 13,200+ participants) found patients using eConsent versus paper had a better understanding of the trial information. Medable, which ranked in the top 8% of software companies on the 2023 Inc. in Phase III trials, respectively.
See if there is a natural history or observational study. I enrolled in the Jain Foundation’s natural history study in 2012, and it tracked me for four years, providing data on my disease progression and biomarkers that are essential if companies are going to become interested in drugdevelopment.
Real-world examples and case studies can showcase the platform's impact. Showcase Success Stories: Share success stories and case studies that highlight how the FDP has improved patient outcomes and enhanced healthcare decision-making. Positive examples will build confidence in the platform's value. Buy, build or partner?
As illustrated in a 2019 study published in JAMA Internal Medicine , the percentage of adults in the United States with a primary care physician has been on the decline for years. As work-from-home technology continues to improve, we expect a positive impact on the research and development side for life sciences organizations.
“We are excited to partner with Debiopharm and redefine the landscape of clinical development with AI,” said Livia Lifes, co-founder and CEO at Neuroute.
Research: Facilitating large-scale studies to better understand the progression of mental illnesses and identify new treatment targets. Public health: Studying the spread of infectious diseases and identifying risk factors. Drugdevelopment: Assessing treatment efficacy and patient adherence.
This article will be a weekly roundup of interesting stories, product announcements, new hires, partnerships, research studies, awards, sales, and more. News and Studies . Research from security vendor Utimaco showed that 63% of U.K. residents would use digital services to access healthcare.
When it comes to incorporating new technology into drugdevelopment and clinical practice, the best place to start is with the patients. Raw data access also allows for data reprocessing as algorithms are updated, and for evaluation of data by the broader scientific community as wearable DHTs are incorporated into more studies.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content